05th November, 2025: Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September 2025.

Financial Highlights for Q2FY26

• Revenue from operations increased by 16% to Rs.1,910 Cr.
• EBITDA increased by 26% to Rs. 325 Cr
• EBITDA Margin at 17% of revenue
• Reported Profit After Tax at Rs.185 Cr. up by 20%.

Commenting on the results, Mr. Shaunak Amin MD, Alembic Pharmaceuticals Limited, said, Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16% and pre-R&D EBITDA margin of 26%. Our R&D investment, at around 10% of revenue, reflects our commitment to building a strong pipeline for future growth. We continue to focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery. During the quarter, we completed the acquisition of Utility Therapeutics that provides a segway in to branded drugs in the US.

Operational Highlights India Branded Business

• India Branded Business delivered a 5% YoY growth, reaching ₹639 Cr in revenue for the quarter.
• Gynaecology, Ophthalmology and Animal healthcare segments have demonstrated accelerating performance.
• Cough & Cold segments grew in line with market performance, with robust operational execution.
• Successfully introduced 2 new products during the quarter.

International Business

• US Generics grew by 21% to Rs. 566 Cr. for the quarter.
• 3 Launches in the US market during the quarter.
• Ex-US International Generics grew by 31% to Rs. 392 Cr. for the quarter.
• 6 ANDA approvals received during the quarter, 226 Cumulative ANDA approvals.

API Business

• API business grew by 15% to Rs. 261 Cr. for the quarter.